MedTrace Logo

Spondylitis Trial of Apremilast for Better Rheumatic Therapy

NCT00944658 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-12-06

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of apremilast in AS as measured by improvement in patients' signs and symptoms of the disease and changes in imaging. Additionally the safety and tolerability of apremilast in AS will be assessed.

Conditions

Interventions

DRUG

Apremilast

10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks

DRUG

Placebo (sugar pill)

twice a day

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Imperial College London

    lead OTHER

Principal Investigators

  • Peter Taylor · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00944658 on ClinicalTrials.gov